Innospec Inc. (IOSP) Q1 2026 Earnings Call Transcript
Innospec (IOSP) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.42 per share a year ago.
Innospec (IOSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to IOSP stock based on the movements in the options market lately.
Innospec (IOSP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Innospec (IOSP) reported earnings 30 days ago. What's next for the stock?
Innospec is positioned as a likely beneficiary of energy shortages and rising oil prices, supplying vital chemicals for oil extraction and refining. IOSP trades at a 50% discount to sector P/E and EV/EBITDA multiples, despite a debt-free balance sheet and strong free cash flow generation. Operational catalysts include potential recovery in oilfield services, resolution of the Mexico crisis, and increased demand from geopolitical disruptions.
IOSP faces a storm-hit start to 2026 as lost Performance Chemicals volumes delay recovery, leaving Fuel Specialties to steady results until a second-half rebound.
IOSP faces a storm-hit start to 2026 with weaker H1 earnings with recovery now hinges on a second-half rebound in Performance Chemicals and Oilfield Services.
Innospec Inc. (IOSP) Q4 2025 Earnings Call Transcript
Innospec (IOSP) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.41 per share a year ago.
Innospec has faced significant margin pressure in Performance Chemicals and overall weakness in Oilfield Services, driving a 20% share price decline. Secular challenges like consumer down-trading and higher oleochemical costs have sharply contracted margins, but these headwinds should be largely cyclical. Management is implementing self-help initiatives and expects product launches in late 2025 to support a return to growth by 2026.